Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Short Interest Update

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) was the recipient of a significant increase in short interest in the month of July. As of July 31st, there was short interest totaling 126,080 shares, an increase of 424.7% from the July 15th total of 24,029 shares. Currently, 5.3% of the shares of the company are sold short. Based on an average trading volume of 6,655,441 shares, the days-to-cover ratio is currently 0.0 days.

Lakewood-Amedex Biotherapeutics Trading Down 3.8%

Lakewood-Amedex Biotherapeutics stock traded down $0.09 during midday trading on Friday, reaching $2.24. 34,766 shares of the stock traded hands, compared to its average volume of 1,308,943. The stock has a fifty day moving average price of $3.45. The firm has a market cap of $5.31 million and a price-to-earnings ratio of -1.12. Lakewood-Amedex Biotherapeutics has a fifty-two week low of $1.66 and a fifty-two week high of $98.20.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last announced its quarterly earnings results on Friday, August 14th. The company reported ($2.75) EPS for the quarter. On average, research analysts expect that Lakewood-Amedex Biotherapeutics will post 2.52 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on LABT. Weiss Ratings initiated coverage on Lakewood-Amedex Biotherapeutics in a research note on Monday, July 20th. They issued a “sell (e-)” rating for the company. Wall Street Zen downgraded Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Lakewood-Amedex Biotherapeutics has a consensus rating of “Sell”.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.